07 Jul HAWK Study for Wet Age-Related Macular Degeneration
The purpose of this study is to find out what effect a new drug called RTH258 has on people with wet AMD. To do this, we will compare it to another anti-VEGF drug called Eylea® (generic name: aflibercept). RTH258 is still experimental and is not approved by the U.S. Food and Drug Administration. Eylea® is approved by the U.S. Food and Drug Administration for use in patients with this condition.
A total of about 990 people are expected to participate in this study worldwide, with up to 12 people at the Medical College of Wisconsin.
Potential participants may qualify for the study if they meet all of the inclusion criteria and none of the exclusion criteria.
-Wet AMD (will be confirmed by a study doctor).
-50 years of age or older.
-Previously received any treatment for Wet AMD, excluding vitamin supplements, in the study eye.
-Steroid injection in the study eye.
-Eye surgery in the study eye.
-Stroke or heart attack within the past 3 months.
Full Study Title
A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration
Study ID: NCT02307682
Medical College of Wisconsin- The Eye Institute
Dr. William Wirostko, M.D.